On or around 07/21/2017 (Stipulation and order of dismissal (voluntary dismissal))
Filing Date: April 17, 2017
According to the law firm press release, the complaint alleges that, throughout the class period, TherapeuticsMD engaged in a scheme to deceive the market and cause the Company's stock to trade at artificially inflated prices. In particular, the complaint alleges that TherapeuticsMD made false and/or misleading statements and/or failed to disclose that: (i) the Company's New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the deficient NDA would likely cause a delay of the FDA's potential approval of the TX-004HR NDA.
On April 10, 2017, TherapeuticsMD issued a press release announcing that the U.S. Food and Drug Administration had identified deficiencies in its NDA for TX-004HR. Following this news, shares of TherapeuticsMD fell more than 19% to close at $6.20 per share on April 10, 2017.
Pursuant to a Notice of Voluntary Dismissal, this case was ordered dismissed on July 21, 2017.
Company & Securities Information
Defendant: TherapeuticsMD, Inc.
Industry: Major Drugs
Headquarters: United States
Ticker Symbol: TXMD
Company Market: New York SE
Market Status: Public (Listed)
About the Company & Securities Data
"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.
In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
First Identified Complaint
Joseph Paoli, et al. v. TherapeuticsMD, Inc., et al.
COURT: S.D. Florida
DOCKET #: 17-CV-80473
JUDGE: Hon. Robin L. Rosenberg
DATE FILED: 04/17/2017
CLASS PERIOD START: 07/07/2016
CLASS PERIOD END: 04/09/2017
PLAINTIFF FIRMS NAMED IN COMPLAINT:
Cullin O'Brien Law, P.A. 6541 NE 21st Way , Cullin O'Brien Law, P.A. , FL 33308 561-676-6370 561-320-0285 ·